Diabetic Kidney Disease (DKD) Market to Reach USD 9.87 Billion by 2034

Pune, India - December 2025 - The global Diabetic Kidney Disease (DKD) Market, valued at USD 5.61 billion in 2024, is projected to reach USD 9.87 billion by 2034, growing at a 5.9% CAGR (2025-2034), according to Exactitude Consultancy. Increasing rates of type 2 diabetes, enhanced CKD screening, and strong uptake of SGLT2 inhibitors and RAAS-modulating therapies are steering market expansion.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71984

Market Summary
The DKD Market is growing swiftly as diabetic kidney disease-also known as diabetic nephropathy-remains one of the most common and serious complications of type 1 and type 2 diabetes. DKD significantly increases the risk of chronic kidney disease (CKD), cardiovascular mortality, and progression to end-stage renal disease (ESRD).

Key pathophysiological drivers include hyperglycemia, hypertension, RAAS activation, inflammation, and glomerular injury. Diagnosis relies on urine albumin-to-creatinine ratio (ACR), eGFR measurement, serum creatinine, kidney imaging, and risk-stratification models.

The treatment landscape has transformed with the rise of SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin), GLP-1 receptor agonists, finerenone (MRA), and standard RAAS blockers such as ACE inhibitors and ARBs. These therapies offer renal protection, cardiovascular risk reduction, and improved long-term patient outcomes.

North America leads with strong therapy adoption and large diabetic populations, while Asia-Pacific is the fastest-growing region, driven by rising metabolic disease, urbanization, and improved CKD screening programs.

Key Takeaways
• 2024 Market Size: USD 5.61 Billion
• 2034 Forecast: USD 9.87 Billion
• CAGR: 5.9% (2025-2034)**
• SGLT2 inhibitors and MRAs transforming DKD management
• Early screening for microalbuminuria expanding rapidly
• Asia-Pacific accounts for the largest increase in new DKD cases

Market Drivers
• Global rise in type 2 diabetes and obesity
• Strong clinical evidence supporting SGLT2 inhibitors for renal protection
• Increasing use of RAAS-modulating and anti-inflammatory therapies
• Expansion of CKD screening and risk prediction tools
• Growing investment in renal biomarkers and precision nephrology

Segmentation Snapshot
By Drug Class
• SGLT2 Inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) - Fastest-Growing Segment
• RAAS Blockers (ACE inhibitors, ARBs)
• Non-steroidal MRAs (Finerenone)
• GLP-1 Receptor Agonists
• Statins & Cardiovascular Adjunct Therapies
• Emerging Anti-inflammatory & Anti-fibrotic Agents

By Diagnostic Method
• Urine Albumin-to-Creatinine Ratio (ACR)
• Estimated Glomerular Filtration Rate (eGFR)
• Serum Creatinine
• Renal Imaging (Ultrasound, CT, MRI)
• Biomarker Testing (NGAL, KIM-1, TNFR1/2)

By Disease Stage
• Early DKD (Stages 1-2)
• Moderate DKD (Stage 3)
• Advanced DKD (Stages 4-5)

By End User
• Hospitals
• Nephrology Centers
• Diabetes Clinics
• Diagnostic Laboratories
• Research Institutions

By Region
• North America (Largest Market)
• Europe
• Asia-Pacific (Fastest Growth)
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/71984/diabetic-kidney-disease-dkd-market

Recent Developments
• Expanded approvals for SGLT2 inhibitors for slowing CKD progression.
• Finerenone demonstrating long-term renal and cardiovascular benefits.
• Development of AI-based CKD progression prediction models.
• Increased integration of DKD care pathways into diabetes management platforms.

Expert Quote - Irfan Tamboli, Business Development Executive
"Diabetic kidney disease represents a major global health burden. With breakthroughs in SGLT2 inhibitors and mineralocorticoid receptor antagonists, DKD management has entered a transformational era of renal and cardiovascular protection."

Conclusion
The Diabetic Kidney Disease Market will continue growing through 2034 as diabetes prevalence rises, renal-protective therapies become mainstream, and screening programs expand worldwide. Companies focusing on SGLT2/RAAS innovations, CKD biomarkers, and digital nephrology solutions are best positioned to lead the next growth cycle.

This report is also available in the following languages : Japanese (糖尿病性腎臓病(DKD)市場), Korean (당뇨병성 신장 질환(DKD) 시장), Chinese (糖尿病肾病(DKD)市场), French (Marché de la maladie rénale diabétique (MRD)), German (Markt für diabetische Nierenerkrankungen (DKD)), and Italian (Mercato della malattia renale diabetica (DKD)), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71984

Related Reports

Hyperuricemia Market
https://exactitudeconsultancy.com/reports/72030/hyperuricemia-market

Renal Insufficiency Market
https://exactitudeconsultancy.com/reports/72044/renal-insufficiency-market

Secondary Hyperparathyroidism Market
https://exactitudeconsultancy.com/reports/72046/secondary-hyperparathyroidism-market

Rare Kidney Diseases Market
https://exactitudeconsultancy.com/reports/72615/rare-kidney-diseases-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.